LON:INDV - Indivior Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 106.45 +7.11 (+7.16 %) (As of 02/22/2019 04:00 PM ET)Previous CloseGBX 106.45Today's RangeGBX 99.46 - GBX 110.8052-Week RangeGBX 246.50 - GBX 436.60Volume4.32 million shsAverage Volume2.44 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in Richmond, Virginia. Receive INDV News and Ratings via Email Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV Previous Symbol CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees900 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Indivior (LON:INDV) Frequently Asked Questions What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." What price target have analysts set for INDV? 5 brokerages have issued 12-month price targets for Indivior's shares. Their forecasts range from GBX 114 to GBX 398. On average, they expect Indivior's share price to reach GBX 234.40 in the next twelve months. This suggests a possible upside of 120.2% from the stock's current price. View Analyst Price Targets for Indivior. What is the consensus analysts' recommendation for Indivior? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Indivior. Has Indivior been receiving favorable news coverage? Press coverage about INDV stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Indivior earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Indivior's key competitors? Some companies that are related to Indivior include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acreage (ACRGF), Activecare (ACAR), Advanced Accelerator Application (AAAP), Advanced Medical Solutions (AMS), Advanced Oncotherapy (AVO), AEGON (AGN), Airware Labs (AIRW) and Akers Biosciences (AKR). What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Reckitt Benckiser Group (RB), INDIVIOR PLC/S (INVVY), Pharming Group (PHGUF), Aradigm (ARDM), Regeneron Pharmaceuticals (REGN), Pacira Pharmaceuticals (PCRX), Concordia International (CXR), Merck & Co., Inc. (MRK), Bigblu Broadband (BBB) and Lakehouse (LAKE). Who are Indivior's key executives? Indivior's management team includes the folowing people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations How do I buy shares of Indivior? Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 106.45. What is Indivior's official website? The official website for Indivior is http://indivior.com/. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. MarketBeat Community Rating for Indivior (LON INDV)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 416 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 620MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote "Outperform" if you believe INDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: What is the Current Ratio?